Use access key #2 to skip to page content.
$0.54 0.04 (7.98%)
10/7/2008 3:40 PM

Hana Biosciences, Inc. (HNAB)

CAPS Rating:
No stars

A development stage biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care.

View All Commentary (HNAB)

Recs

1

Avatar Joe1962 (< 20) Submitted: 3/12/07 1:05 PM : Underperform Start Price: $4.04 HNAB Score: 57.73

Into development, and with many competitiors, a risky stock. With the change of directors, Im sure it will take a bit of time to get things rolling. The phase clinicals take time. If something gets into phase three, and eventually passes, then the stock will go up. A good low stock to buy into, and hold at the moment, but it could be bought out too, small volumn.

Report this Post Replies: 0 | Reply

Featured Broker Partners